Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.53 |
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 6/20 | 0.47 |
| ▸ | TDO2 | P48775 | 4/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29981288 | 1.00 | METAP2 (0.53) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL17875686 | 0.79 | TDO2 (0.66) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL14487466 | 0.79 | METAP2 (0.56) | METAP2NOS1IDO1TDO2DYRK1A | |
| SCHEMBL17739410 | 0.76 | METAP2 (0.53) | METAP2NOS1IDO1TDO2DYRK1A | |
| SCHEMBL2289231 | 0.76 | IDO1 (0.61) | METAP2NOS1IDO1TDO2DYRK1A | |
| SCHEMBL16682088 | 0.76 | METAP2 (0.53) | METAP2NOS1IDO1TDO2DYRK1A | |
| SCHEMBL20176611 | 0.76 | NOS1 (0.50) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL14737953 | 0.76 | METAP2 (0.53) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL1415060 | 0.76 | NOS1 (0.50) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL2007139 | 0.76 | IDO1 (0.59) | METAP2NOS1AXLIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111995577-A | Synthetic method of 4-fluoro indazole 3-carbonitrile or derivatives thereof | 上海代为化学科技有限公司 | 2020-11-27 | — | — | CN | claimed |
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250250237-A1 | ALKYLAMINE OR HETEROALKYLAMINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2015116886-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| EP-2747755-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | Lead Discovery Center GmbH (DE) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026874-A1 | CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA | LEAD DISCOVERY CENTER GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| CN-101679288-A | Indazoles for treating estrogen receptor beta mediated diseases | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250237-A1 | ALKYLAMINE OR HETEROALKYLAMINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS3, NOS2, NOS1 | METAP2 2416/4885NOS1 3/4885AXL 2077/4885 |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | METAP2 474/4885NOS1 3010/4885AXL 467/4885 |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | METAP2 4271/4885NOS1 3015/4885AXL 678/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | METAP2 4406/4885NOS1 4841/4885AXL 3281/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | METAP2 3641/4885NOS1 4832/4885AXL 1253/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | METAP2 4406/4885NOS1 4841/4885AXL 3281/4885 |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GPER1, ESR2, ESRRB | METAP2 2445/4885NOS1 2587/4885AXL 3533/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | METAP2 4304/4885NOS1 4037/4885AXL 4181/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | METAP2 4127/4885NOS1 2383/4885AXL 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.